Single dose of HPV vaccine: JCVI interim advice

Statement of key considerations and evidence

10 February 2022

The Joint Committee on Vaccination and Immunisation (JCVI) is an expert scientific advisory committee which advises the UK government on matters relating to vaccination and immunisation.

The JCVI has been considering the issue of a potential move to one dose of the HPV vaccine for several years. Indeed, the committee was aware of the potential for one dose as far back as 2018.

The first major review of a one-dose schedule took place in June 2020 and although the evidence considered indicated the direction of travel was towards a one-dose schedule the committee agreed that it would like to see more data, particularly on the 9-valent vaccine, before providing advice on the HPV programme.

JCVI met in December 2021 to consider the latest evidence on the protective efficacy and immunogenicity of one dose of HPV vaccine including that from ongoing clinical trials of a single-dose schedule using the 9-valent vaccine.

JCVI considers it is now ready. to issue interim advice on a move to a one-dose schedule for the routine adolescent programme. This statement sets out the key considerations and evidence supporting the conclusions and advice of the committee.

The full independent report is availlable here.

View other News Articles